KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Common Equity (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Common Equity for 18 consecutive years, with $1.1 billion as the latest value for Q1 2026.

  • For Q1 2026, Common Equity rose 152.35% year-over-year to $1.1 billion; the TTM value through Mar 2026 reached $1.1 billion, up 152.35%, while the annual FY2025 figure was $789.2 million, 1076.33% up from the prior year.
  • Common Equity hit $1.1 billion in Q1 2026 for Alnylam Pharmaceuticals, up from $789.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $1.1 billion in Q1 2026 and bottomed at -$408.1 million in Q2 2023.
  • Average Common Equity over 5 years is $114.7 million, with a median of $32.4 million recorded in 2024.
  • Year-over-year, Common Equity plummeted 331.84% in 2023 and then soared 8270.56% in 2025.
  • Alnylam Pharmaceuticals' Common Equity stood at -$158.2 million in 2022, then tumbled by 39.45% to -$220.6 million in 2023, then skyrocketed by 130.41% to $67.1 million in 2024, then soared by 1076.33% to $789.2 million in 2025, then soared by 36.27% to $1.1 billion in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $1.1 billion, $789.2 million, and $233.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.